Neurocrine Biosciences IncNBIX
Price$140.71Intrinsic value$383.60173% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $3.4B+43.2% YoYTTM through 30 Jun 2026
Net Income $705.5M+106.7% YoYTTM through 30 Jun 2026
Free Cash Flow $870.4MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin23.7%
Operating Margin23.6%
Net Margin20.9%

Returns

19.6%ROE
13.6%ROA
21.0%ROIC

Balance Sheet Health

Debt / Equity0.00x
Current Ratio2.93x
Net Debt-$1.4Bnet cash position
Cash & Equivalents$332.4M

Quality Metrics

Altman Z-Score6.69
Piotroski F-Score5 / 9
FCF Margin25.8%
Rule of 4041.4
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $2.9B
Diluted EPS$6.84TTM
'19'20'21'22'23'24'25
FY2025: $4.67

Dividend

No dividend

Capital Allocation

Capex Intensity0.8%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.